Switch to:
More From Other Websites
ADYNOVATE PHASE 3 EFFICACY AND SAFETY ... Jul 26 2016
7:03 am Shire plc to present additional data of ADYNOVATE Phase 3 efficacy and safety at the... Jul 26 2016
ADYNOVATE Phase 3 Efficacy and Safety Data in Children to be Showcased During International Congress... Jul 26 2016
Specialty Pharma: Earnings Better Be Good…or Else Jul 25 2016
ONIVYDE® Receives Positive ... Jul 25 2016
Merrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union Jul 25 2016
ONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of... Jul 25 2016
How Analysts Think Investors Should Play Vertex Pharmaceuticals Jul 21 2016
Valeant & Endo: Imagining a World With No Drug Pricing Controversies Jul 21 2016
Shire Launches Pediatric Indication for Immunodeficiency Treatment HyQvia in Europe Jul 21 2016
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Jul 20 2016
Shire Reinforces Commitment in Hematology with Robust Data Presented at International Congress of... Jul 19 2016
Shire Could Divest ADHD Treatment, Other Assets, for More Upside Post-Baxalta Jul 14 2016
Coverage Initiated on Select Healthcare Stocks Jul 14 2016
Price Monitoring Extension Jul 14 2016
Company News for July 13, 2016 Jul 13 2016
Multimedia assets now available: FDA Approves Shire's Xiidra™ (lifitegrast ophthalmic solution) 5%... Jul 12 2016
Shire's (SHPG) Dry Eye Disease Drug Xiidra Gets FDA Nod Jul 12 2016
Shire shares up after US approves dry-eye disease treatment Jul 12 2016
Shire Stock Up As Eye Drug Wins Early Approval, Broad Label Jul 12 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK